Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 52

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of DAC Combined with CAG Regimen (decitabine in combined with aclacinomycin, cytarabine and G-CSF) As a Second Induction Regimen Compared with Non-DAC Regimen for Acute Myeloid Leukemia Who Failed the First Course of Standard Induction IA Chemotherapy

Yili Chen, Min Dai, Qifa Liu, MD

Blood (2019) 134 (Supplement_1): 5104.

https://doi.org/10.1182/blood-2019-127947

Published: 2019

Journal Articles

Decitabine, Etoposide-Based Regimen Greatly Improved T53 Mutation Elderly AML/MDS Survival By Activating Notch1 Signaling Pathway

Jiexian Ma, MD, Xie Yanhui, Wu Min, Sun Shunrong

Blood (2019) 134 (Supplement_1): 5409.

https://doi.org/10.1182/blood-2019-125735

Published: 2019

Journal Articles

Prospective Evaluation of Allogeneic HSCT at the First Remission for Younger Adults with FLT3 -ITD Positive Acute Myeloid Leukemia: The JALSG AML209-FLT3-SCT Study

Blood (2019) 134 (Supplement_1): 1328.

https://doi.org/10.1182/blood-2019-124394

Published: 2019

Journal Articles

Efficacy and Safety of C-CAG Regimen (cladribine in combination with granulocyte colony-stimulating factor, low-dose cytarabine and aclarubicin) in Patients with Refractory/Relapsed Acute Myeloid Leukemia: A Phase 2, Single Center, Single Arm Study

Hua Wang, MD, Yue Lu

Blood (2018) 132 (Supplement 1): 3984.

https://doi.org/10.1182/blood-2018-99-113292

Published: 2018

Journal Articles

A Double Priming Induction Regimen for Acute Myeloid Leukemia with Inferior PS Among Resource Limited Areas

Stephen Liang, MD, Siliang Chen, Xiaoli Huang, Zheyuan Qin, Sanbin Wang

Blood (2018) 132 (Supplement 1): 5173.

https://doi.org/10.1182/blood-2018-99-118732

Published: 2018

Journal Articles

Efficacy and Safety of Decitabine in Combination with G-CSF, Low-Dose Cytarabine and Mitoxantrone in Pediatric Refractory and Relapse Acute Myeloid Leukemia and MDS-Raebt

Liyan Fan, MD, Aili Chen, MD, Yixin Hu, MD, Peifang Xiao, MD, Jun Lu, MD, Jie Li, MD, Hailong He, MD, Yi Wang, MD, Shaoyan Hu, MD PhD

Blood (2018) 132 (Supplement 1): 5175.

https://doi.org/10.1182/blood-2018-99-117850

Published: 2018

Journal Articles

Survival Benefit of Novel Drug Combinations Using Hypomethylating Agents for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia: A Systemic Review

Pavan Tenneti, MD, Keri R Maher, DO, Mohamed Mokhtar Bakr, MD, Umar Zahid, MD MPH, Saad Ullah Malik, MD, Warda Faridi, MD, Faiz Anwer, MD

Blood (2018) 132 (Supplement 1): 5182.

https://doi.org/10.1182/blood-2018-99-115810

Published: 2018

Journal Articles

Chidamide, Decitabine, Cytarabine, Aclarubicin, and Granulocyte Colony-Stimulating Factor (CDCAG) in Adults with Relapsed/Refractory Acute Myeloid Leukemia: Final Results from a Phase 1/2 Study

Lixin Wang, PhD MD, Guofeng Chen, MD, Jianliang Shen, MD PhD, Jianmin Luo, Meiyun Fang, MD, Xudong Wei, MD, Yinghua Li, MD, Zhuogang Liu, MD, Yin Zhang, MD, Sujun Gao, PhD, Xin Wang, MD PhD, Xiaoning Gao, MD PhD, Wei Zhou, MD, Yigai Ma, MD, Hui Liu, MD, Xinquan Li, MD PhD, Linhua Yang, MD, Li Yu, MD PhD

Blood (2018) 132 (Supplement 1): 2707.

https://doi.org/10.1182/blood-2018-99-111761

Published: 2018

Journal Articles

Favorable Inductive Remission Rate of Decitabine Combined Chemotherapy on < 60-Years of Age MDS-like AML in the First Course

Fengqi Liu, MD, Xiuzhen Tong, MD, Zhenhai Zhou, MD, Dong Zheng, MD, Hehua Wang, MD, Junru Liu, MD, Beihui Huang, MD, Chang Su, MD, Waiyi Zou, MD, Duorong Xu, MD, Juan Li, PhD

Blood (2018) 132 (Supplement 1): 2711.

https://doi.org/10.1182/blood-2018-99-113748

Published: 2018

Journal Articles

A Pilot Prospective Single-Arm Clinical Study on Decitabine Plus CAG or IA Followed with HLA-Mismatched Nonmyeloablative Transplantation (micro transplantation) on De Novo Elderly Acute Myeloid Leukemia and Int-2/High Risk Myelodysplastic Syndrome Patients

Jie Sun, Yan Huang, Weijia Huang, Lizhen Liu, Jimei Ge, Yunfei Qiu, Zhang En Fan, Xiaorong Hu, Zhen Cai, MD PhD, He Huang, MD PhD

Blood (2018) 132 (Supplement 1): 2188.

https://doi.org/10.1182/blood-2018-99-119136

Published: 2018

Journal Articles

The Synergy of Vitamin C with Decitabine Activates TET2 in Leukemic Cells and Significantly Improves Overall Survival in Elderly Patients with Acute Myeloid Leukemia

Huihui Zhao, Zhu Huayuan, Zhu Yu, Jianyong Li, MD PhD, Sixuan Qian, PhD MD

Blood (2017) 130 (Supplement 1): 1339.

https://doi.org/10.1182/blood.V130.Suppl_1.1339.1339

Published: 2017

Journal Articles

Efficacy and Safety of Decitabine in Combination with G-CSF, Low-Dose Cytarabine and Aclarubicin in MDS-EB and AML-MRC

Jing Liu, MD PhD, Jinsong Jia, MD, Li-Zhong Gong, MD, Shen-ye Lu, MD, Hong-Hu Zhu, MD, Xiao-Jun Huang, MD, Hao Jiang, MD

Blood (2017) 130 (Supplement 1): 2980.

https://doi.org/10.1182/blood.V130.Suppl_1.2980.2980

Published: 2017

Journal Articles

A Retrospective Analysis of Ultra Low-Dose Decitabine Combined with Gha Regimen in Patients with Middle and High Risk Myelodysplastic Syndrome

Wang Xiaman, PhD, Ju Bai, Yun Yang, Jianli Wang, Wanggang Zhang, Xingmei Cao, Yinxia Chen, Yanping Song, Hongli Chen, PhD, Yue Peng, PhD, Aili He, PhDMD, Fangxia Wang

Blood (2016) 128 (22): 5484.

https://doi.org/10.1182/blood.V128.22.5484.5484

Published: 2016

Journal Articles

Additional Decitabine Did Not Improve Outcomes of Elder Acute Myeloid Leukemia Patients Based on Microtransplantation with Cytarabine and Anthracycline Chemotherapy

Kaixun Hu, MD, Yajing Huang, MD, Huisheng Ai, MD, Mei Guo, Yu Changlin, Qiao Jianhui, Qiyun Sun, Zheng Dong, Hongli Zuo, Bo CAI, Xuliang Shen, MD

Blood (2015) 126 (23): 1318.

https://doi.org/10.1182/blood.V126.23.1318.1318

Published: 2015

Journal Articles

Azacitidine (AZA) Combination Therapy with Low-Dose AraC for Aggressive Type MDS, Overt AML, and AML Patients

Manabu Hirai, MDPhD, Atsushi Inoue, MD, Mitsuharu Hashimura, MD, Mizuki Aimoto, MD PhD, Erina Sakamoto, MD PhD

Blood (2015) 126 (23): 1688.

https://doi.org/10.1182/blood.V126.23.1688.1688

Published: 2015

Journal Articles

High Risk Older AML Patients May be Benefited from the Treatment of Decitabine Combined Wih CAG Regimens

Xia Xiao, MD, Mingfeng Zhao, MDPhD, Qi Deng, MD, Qing Li, MD, Juan Mu, MD, Li Geng, MD, Yuming Li, MD

Blood (2014) 124 (21): 4953.

https://doi.org/10.1182/blood.V124.21.4953.4953

Published: 2014

Journal Articles

Azacitidine (AZA) Combination Therapy with Low-Dose AraC Is Well Tolerated and Highly Effective for MDS with Overt Leukemia

Manabu Hirai, MDPhD, Mizuki Aimoto, MD, Atsushi Inoue, MD, Mitsuharu Hashimura, MD, Erina Sakamoto, MD PhD, Hirohisa Nakamae, Masayuki Hino, MD PhD

Blood (2014) 124 (21): 3260.

https://doi.org/10.1182/blood.V124.21.3260.3260

Published: 2014

Journal Articles

Decitabine Act As Demethylation Modulators in Acute Myeloid Leukemia for Reversal of Drug Resistance

Zhixiang Wang, MD, Xuejie Jiang, MDPhD, Kaikai Huang, Changxin Yin, Qingxiu Zhong, MD, Qiuhua Zhu, MD, Bingjie Ding, MD, Fan Yi Meng, MD

Blood (2014) 124 (21): 5218.

https://doi.org/10.1182/blood.V124.21.5218.5218

Published: 2014

Journal Articles

Low-Dose Arsenic Trioxide Combined with Aclacinomycin a Synergistically Enhance the Cytotoxic Effect on Human Acute Myelogenous Leukemia KG-1a Cell Line By the Induction of Apoptosis

Yongbin Ye, Xiaojun Xu, Mingwan Zhang, Dafa Qiu, Xiaochun Bai, Jing Wang, Guangyang Weng, Zhou Ruiqing, Ziwen Guo, Huiqing He, Wenfang Yi, Xin He, Guo Kunyuan

Blood (2014) 124 (21): 5303.

https://doi.org/10.1182/blood.V124.21.5303.5303

Published: 2014

Journal Articles

Treatment of Relapsed ACUTE Leukemia after ALLO-HSCT By Salvage Chemotherapy with Low-Dose Cytarabine and Aclarubicin Combined with G-CSF Priming: More Effective and LESS Toxic?

Hua Zhou, Ling Ge, Xiaming Zhu, Huiying Qiu, Zhengming Jin, Miao Miao, Chengcheng Fu, Xiao Ma, Feng Chen, Shengli Xue, Changgeng Ruan, Wu Depei, MD, Xiaowen Tang, MD

Blood (2014) 124 (21): 3733.

https://doi.org/10.1182/blood.V124.21.3733.3733

Published: 2014

NARROW

Efficacy and Safety of DAC Combined with CAG Regimen (decitabine in combined with aclacinomycin, cytarabine and G-CSF) As a Second Induction Regimen Compared with Non-DAC Regimen for Acute Myeloid Leukemia Who Failed the First Course of Standard Induction IA Chemotherapy

Decitabine, Etoposide-Based Regimen Greatly Improved T53 Mutation Elderly AML/MDS Survival By Activating Notch1 Signaling Pathway

Prospective Evaluation of Allogeneic HSCT at the First Remission for Younger Adults with FLT3 -ITD Positive Acute Myeloid Leukemia: The JALSG AML209-FLT3-SCT Study

Efficacy and Safety of C-CAG Regimen (cladribine in combination with granulocyte colony-stimulating factor, low-dose cytarabine and aclarubicin) in Patients with Refractory/Relapsed Acute Myeloid Leukemia: A Phase 2, Single Center, Single Arm Study

A Double Priming Induction Regimen for Acute Myeloid Leukemia with Inferior PS Among Resource Limited Areas

Efficacy and Safety of Decitabine in Combination with G-CSF, Low-Dose Cytarabine and Mitoxantrone in Pediatric Refractory and Relapse Acute Myeloid Leukemia and MDS-Raebt

Survival Benefit of Novel Drug Combinations Using Hypomethylating Agents for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia: A Systemic Review

Chidamide, Decitabine, Cytarabine, Aclarubicin, and Granulocyte Colony-Stimulating Factor (CDCAG) in Adults with Relapsed/Refractory Acute Myeloid Leukemia: Final Results from a Phase 1/2 Study

Favorable Inductive Remission Rate of Decitabine Combined Chemotherapy on < 60-Years of Age MDS-like AML in the First Course

A Pilot Prospective Single-Arm Clinical Study on Decitabine Plus CAG or IA Followed with HLA-Mismatched Nonmyeloablative Transplantation (micro transplantation) on De Novo Elderly Acute Myeloid Leukemia and Int-2/High Risk Myelodysplastic Syndrome Patients

The Synergy of Vitamin C with Decitabine Activates TET2 in Leukemic Cells and Significantly Improves Overall Survival in Elderly Patients with Acute Myeloid Leukemia

Efficacy and Safety of Decitabine in Combination with G-CSF, Low-Dose Cytarabine and Aclarubicin in MDS-EB and AML-MRC

A Retrospective Analysis of Ultra Low-Dose Decitabine Combined with Gha Regimen in Patients with Middle and High Risk Myelodysplastic Syndrome

Additional Decitabine Did Not Improve Outcomes of Elder Acute Myeloid Leukemia Patients Based on Microtransplantation with Cytarabine and Anthracycline Chemotherapy

Azacitidine (AZA) Combination Therapy with Low-Dose AraC for Aggressive Type MDS, Overt AML, and AML Patients

High Risk Older AML Patients May be Benefited from the Treatment of Decitabine Combined Wih CAG Regimens

Azacitidine (AZA) Combination Therapy with Low-Dose AraC Is Well Tolerated and Highly Effective for MDS with Overt Leukemia

Decitabine Act As Demethylation Modulators in Acute Myeloid Leukemia for Reversal of Drug Resistance

Low-Dose Arsenic Trioxide Combined with Aclacinomycin a Synergistically Enhance the Cytotoxic Effect on Human Acute Myelogenous Leukemia KG-1a Cell Line By the Induction of Apoptosis

Treatment of Relapsed ACUTE Leukemia after ALLO-HSCT By Salvage Chemotherapy with Low-Dose Cytarabine and Aclarubicin Combined with G-CSF Priming: More Effective and LESS Toxic?

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only